Costi ed efficacia devono essere scontati allo stesso tasso?

Weinstein MC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21 Keeler EB, Cretin S. Discounting of live-saving and other nonmonetary effects. Management Science 1983; 29(3): 153–62 Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Metodi per la valutazione economica dei programmi sanitari. II ed. Roma: Il Pensiero Scientifico Editore, 2000 Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 1995 Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1997 National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004 Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. The Mario Negri Institute Centre for Health Economics. Pharmacoeconomics 1995; 7(1): 1–6 Attanasio E, Bruzzi P, Capri S, et al. Raccomandazioni per la conduzione degli studi di farmacoeconomia: la guida GISF. Mecosan 1999; 29: 65–72 Department of Health. Policy Appraisal and Health. London: Department of Health, 1996